In addition to affecting lung function, tezepelumab has been shown to significantly reduce exacerbation rates by 62-71% in severe patients with uncontrolled asthma, who are classified with a T2low disease form (low IgE levels and low eosinophil counts) [141]. The gene discussed is IGHE; the disease is asthma.